Bristol-Myers Squibb (NYSE:BMY) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported $0.94 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.09, Bloomberg Earnings reports. The firm had revenue of $5.19 billion for the quarter, compared to analyst estimates of $5.25 billion. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period last year, the company earned $0.84 EPS. Bristol-Myers Squibb updated its FY18 guidance to $3.35-3.45 EPS.
Shares of NYSE BMY traded up $0.13 during mid-day trading on Thursday, hitting $51.89. 9,383,386 shares of the stock traded hands, compared to its average volume of 8,738,044. The company has a quick ratio of 1.43, a current ratio of 1.55 and a debt-to-equity ratio of 0.59. Bristol-Myers Squibb has a 52 week low of $50.56 and a 52 week high of $70.05. The firm has a market capitalization of $84,208.63, a PE ratio of 17.24, a P/E/G ratio of 1.39 and a beta of 0.96.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, May 1st. Investors of record on Friday, April 6th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, April 5th. This represents a $1.60 annualized dividend and a dividend yield of 3.08%. Bristol-Myers Squibb’s dividend payout ratio is presently 53.16%.
A number of brokerages have recently weighed in on BMY. BMO Capital Markets reiterated a “sell” rating and issued a $47.00 price objective on shares of Bristol-Myers Squibb in a research report on Thursday. Vetr lowered Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 price objective on the stock. in a research report on Thursday, February 8th. Leerink Swann lifted their price objective on Bristol-Myers Squibb from $71.00 to $76.00 and gave the stock a “positive” rating in a research report on Tuesday, February 6th. Citigroup set a $78.00 price objective on Bristol-Myers Squibb and gave the stock a “buy” rating in a research report on Friday, February 16th. Finally, Jefferies Group set a $70.00 price objective on Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Friday, March 23rd. Three research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eight have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $64.23.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. WINTON GROUP Ltd purchased a new position in shares of Bristol-Myers Squibb in the second quarter worth $239,000. 1st Global Advisors Inc. purchased a new position in shares of Bristol-Myers Squibb in the second quarter worth $3,351,000. Keel Point LLC raised its stake in shares of Bristol-Myers Squibb by 0.6% in the second quarter. Keel Point LLC now owns 6,325 shares of the biopharmaceutical company’s stock worth $352,000 after purchasing an additional 39 shares during the last quarter. Verition Fund Management LLC raised its stake in shares of Bristol-Myers Squibb by 1.0% in the second quarter. Verition Fund Management LLC now owns 8,190 shares of the biopharmaceutical company’s stock worth $456,000 after purchasing an additional 80 shares during the last quarter. Finally, Piedmont Investment Advisors LLC raised its stake in shares of Bristol-Myers Squibb by 22.5% in the second quarter. Piedmont Investment Advisors LLC now owns 434,496 shares of the biopharmaceutical company’s stock worth $24,210,000 after purchasing an additional 79,842 shares during the last quarter. Institutional investors own 71.58% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.